The Day In Review: Enzon Pharmaceuticals, Inc. Buys And Sells Drug Progams

Enzon in-licensed cancer drugs from Santaris Pharma A/S and out-licensed another cancer drug to Cambridge Antibody; Adams Respiratory bought a manufacturing plantit sold two years ago back from Cardinal Health for $28 million; Genzyme is launching a test for B-cell chronic lymphocytic leukemia; Teva is set to begin a Phase III trial of a higher dose of Copaxone, its multiple sclerosis drug; GlaxoSmithKline applied for US and European approval of a new hay fever drug; Inspire began a Phase III trial of its drug for cystic fibrosis; QLT will buy back up to 13 million of its shares; and Nektar will put its UK and supercritical fluid technology operations up for sale. The Centient Biotech 200™ fell 40 points to 3637.17, a loss of 1.10%. More details...